Good morning. I'm James Helmin from the Washington Post and this is the Daily

202 for Wednesday, September 23rd. In today's news, Senate Republicans race to confirm President Trump's Supreme Court

nominee before Halloween, and it's probably going to be Amy Coney Barrett.

A government shutdown is averted, at least until after the election.

And mine executives are caught on hidden camera bragging about their influence over politicians.

But first, the big idea.

The first coronavirus vaccine that aims to protect people with a single shot has entered

the final stages of testing in the United States

in an international trial that will recruit up to 60,000 participants.

The experimental vaccine being developed by Pharmaceutical Giant Johnson and Johnson is the fourth vaccine to enter the large phase three trials in the US that will determine whether they are safe and effective.

Paul Stouffles, the chief scientific officer at J&J,

predicted to our science writer Carolyn Johnson

that there may be enough data to have results by the end of the year

and he said that the company plans to manufacture 1 billion doses next year.

Three other vaccine candidates have a head start with US trials that began earlier in the summer,

but the vaccine being developed by Janssen Pharmaceuticals, which is a division of J&J, has several advantages that could make it logistically much easier to administer and distribute if it's safe and effective.

The company is initially testing a single administer and distribute if it's safe and effective.

The company is initially testing a single dose,

whereas the other vaccines being tested in the US require a return visit to the doctor

and a second shot three to four weeks after the first one

to trigger a protective immune response.

The J&J vaccine can also be stored in liquid form

...